About: Abciximab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Abciximab Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4262-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4263-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8121459 # Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12939213 # FDA label (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors. (en)
http://linked.open...ugbank/indication	Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting. (en)
sameAs	Abciximab
Title	Abciximab (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/drugbank/DB00054 http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/national-drug-code-directory/0002-7140-01 http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/pharmgkb/PA448006 http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/kegg-drug/D02778 http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/wikipedia/Abciximab
http://linked.open...mechanismOfAction	Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. By binding to the vitronectin receptor (also known as the αvβ3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion. (en)
http://linked.open...drugbank/packager	Breckenridge Pharmaceuticals Bryant Ranch Prepack Cadila Healthcare Ltd. Boehringer Ingelheim Ltd.
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/1341357
http://linked.open.../drugbank/synonym	7E3 antibody (en) antiGPIIBIIIa (en) 7E3 (en) C7E3 (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/92-00-00
foaf:page	http://www.drugs.com/cdi/abciximab.html http://www.rxlist.com/reopro-drug.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4268-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4267-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Abciximab
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	143653-53-6 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...gbank/containedIn	Reopro 2 mg/ml vial
http://linked.open...nk/Hydrophobicity	http://linked.opendata.cz/resource/drugbank/property/271B4265-363D-11E5-9242-09173F13E4C5
http://linked.open...Isoelectric-Point	http://linked.opendata.cz/resource/drugbank/property/271B4266-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B4264-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software